Researcher:
Taşkın, Banu

Profile Picture
ORCID

Job Title

Doctor

First Name

Banu

Last Name

Taşkın

Name

Name Variants

Taşkın, Banu

Email Address

Birth Date

Filters

2020 - 20224

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.61b8b251-5de8-46ac-b5cc-6308ed70a7a4

Search Results

Now showing 1 - 4 of 4
  • Placeholder
    PublicationMetadata only
    COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review
    (Wiley, 2022) Erbaş, Gizem S.; Botsali, Ayşenur; Arı, Canan; Erden, Nihan; Taşkın, Banu; Alper, Fatma Sibel; Vural, Seçil; Undergraduate Student; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; 118467; 189340
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for coronavirus disease 2019 (COVID-19), which manifests as a flu-like respiratory infection affecting multiple organ systems, including the gastrointestinal system, central nervous system, cardiovascular system, skin, and mucosa. In this review, we investigated the literature on specific manifestations of COVID-19 in the oral mucosa. An online literature search in PubMed, Scopus, Google Scholar, and Medline was conducted to retrieve relevant studies on confirmed COVID-19 patients with oral mucosa findings published between December 31, 2019, and April 07, 2021. After an independent review by two authors, 39 articles considering 59 laboratory-confirmed cases of SARS-CoV-2 infection were included in the final analysis. The most common finding, reported in 29 patients (43.9%), was Kawasaki-like syndrome. In addition, oral ulcers including aphthous, hemorrhagic, and necrotic ulcers were reported in 24 patients (36.3%). Other lesions reported included pustules, macules, bullae, maculopapular enanthema, and erythema multiforme-like lesions. Concomitant skin lesions were present in 60.6% of patients. Fever was reported in 86.2% of patients. Forty-eight patients (76.1%) were hospitalized. Loss of taste and smell was present in 30.8% of the patients. A comprehensive understanding of the dermatologic manifestations of COVID-19 can improve and facilitate patient management and referrals.
  • Placeholder
    PublicationMetadata only
    Decrease in inflammation markers with ustekinumab treatment in moderate-severe psoriasis
    (Pamukkale Üniversitesi Tıp Fakültesi, 2021) Vurgun, Eren; Alper, Sibel; N/A; N/A; Taşkın, Banu; Memet, Bachar; Doctor; Doctor; N/A; N/A; Koç University Hospital; N/A; N/A; N/A
    Purpose: Psoriasis is a chronic, inflammatory, and systemic disease. The disease activity is usually measured by Psoriasis Area and Severity Index (PASI), however, further objective laboratory tools are needed. Neutrophillymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) are objectively calculated markers that increase in inflammation. This study aimed to investigate the utility of these markers for follow-up of systemic inflammation and response to treatment. Material and methods: A total of 25 patients who had moderate or severe psoriasis vulgaris, who received ustekinumab treatment were retrospectively evaluated in the study. In patients, pre-treatment PASI, complete blood count parameters, serum CRP levels and NLR, PLR and MPV values in the follow up when they achieved PASI 75 and/or more improvement were recorded. Patients with an additional inflammatory disease or accompanying infection were excluded from the study. Results: While a statistically significant decline was recorded in NLR and PLR (p<0.05), no significant change was observed in MPV and CRP after the therapy success where patients achieved an improvement greater than or equal to PASI 75. Conclusion: We conclude that the correlation with the response to treatment and NLR and PLR levels show that these markers may be beneficial for assessment of disease severity either in combination with current scores or alone. These markers are cost effective predictors that can easily be measured in routine practice. / Giriş: Psoriasis kronik, inflamatuar ve sistemik bir hastalıktır.Psoriasiste hastalık şiddetini ölçmek için Psoriasis Alan Şiddet İndeksi (PAŞİ) yanı sıra daha objektif laboratuar araçlarına ihtiyaç vardır. Nötrofil lenfosit oranı (NLO), trombosit lenfosit oranı (TLO) ve ortalama trombosit hacmi (OTH) çeşitli inflamatuar hastalıklarda arttığı bilinen belirteçlerdir. Bu çalışmada amacımız orta şiddette ve şiddetli psoriasis vulgarisi olan hastalarda NLO, TLO ve OTH değerlerinin ustekinumab tedavisi ile değişimlerini araştırmaktır. Gereç ve yöntem: Çalışmada orta şiddette veya şiddetli psoriasis vulgarisi olup, ustekinumab tedavisi verilen kronik plak tipi psoriasis tanılı 25 hasta retrospektif olarak değerlendirilmiştir. Hastaların tedavi öncesi PAŞİ, tam kan sayımı parametreleri, serum CRP seviyeleri ve PAŞİ 75 ve/veya üzeri başarı elde edildikleri kontrollerindeki değerleri kaydedilmiştir. Tam kan sayımı belirteçleri, OTH ve CRP değeri determine edilmiştir. Ek inflamatuar hastalığı ve eşlik eden enfeksiyonu olanlar çalışma dışı bırakılmıştır. Bulgular: Hastaların PAŞİ 75 başarı ve üzeri elde ettikleri incelemelerde NLO, TLO oranlarında istatistiksel olarak anlamlı düşme (p<0.05) saptanırken OTH ve CRP değerlerinde tedavi başarısı sonrası anlamlı değişiklik izlenmemiştir. Sonuç: NLO ve TLO değerlerinde tedavi yanıtı alınmasıyla anlamlı düşme olduğu gösterdik. Bu göstergeler rutin pratikte kolay ölçülebilen ve maliyet açısından verimli belirteçlerdir.
  • Placeholder
    PublicationMetadata only
    Tattoos in dermatology: demographics, motivations, tattooing practices
    (Wiley, 2021) Altunay, I. K.; Gulsunay, I. E.; Ozkur, E.; Aydin, C.; Manav, V.; Ozden, H. K.; Calikoglu, E. E.; Ertekin, S. S.; Erdogan, H. K.; Kuru, S.; Gurok, N. G.; Ermertcan, A. T.; N/A; Taşkın, Banu; Memet, Bachar; Doctor; Doctor; N/A; Koç University Hospital; N/A; N/A
    N/A
  • Thumbnail Image
    PublicationOpen Access
    COVID-19 presenting with atypical Sweet's syndrome
    (Wiley, 2020) Altuğ, E.; Demirkesen, C.; Çelenbi, İ.; Ferhanoğlu, B.; Alper, S.; Vural, Seçil; Kocatürk Göncü, Özgür Emek; Taşkın, Banu; Faculty Member; Doctor; School of Medicine; 189340; 217219; N/A